Monte Rosa Therapeutics, Inc. Common Stock — Quarterly Financial Statements (NASDAQ:GLUE) | MetaTrader

Open full chart

Financials

Overview Relatórios Statistics Dividends

Quarterly Annual

Market Capitalization 1.4626 B
Employee 147
Founded 2019
CEO N/A
Website www.monterosatx.com
Headquarter Delaware, United States
FIGI BBG00X2VGZQ3
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

1.46 B Market capitalization

Price to earnings ratio

20.58

Price to sales ratio

3.25

Dividends per share

—

Dividend yield %

—

Notícias

Ações da Monte Rosa sobem com resultados de ensaio em câncer de próstata

Monte Rosa shares rise on prostate cancer trial results

Monte Rosa divulga dados positivos de ensaio clínico para medicamento contra câncer de próstata

Monte Rosa reports positive trial data for prostate cancer drug

NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates

Preço-alvo das ações da Monte Rosa elevado para US$ 37 de US$ 27,50 pela Piper Sandler

Monte Rosa stock price target raised to $37 from $27.50 at Piper Sandler

Monte Rosa Therapeutics precifica oferta pública de US$ 300 milhões

Monte Rosa Therapeutics prices $300 million public offering

GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable

Monte Rosa Therapeutics lança oferta pública de US$ 200 milhões